Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
TRIM29 Antibody (TRIM29/1042), Alexa Fluor™ 750, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP247809AF750
Description
TRIM29 Monoclonal specifically detects TRIM29 in Human samples. It is validated for Western Blot.Specifications
TRIM29 | |
Monoclonal | |
Alexa Fluor 750 | |
50mM Sodium Borate with 0.05% Sodium Azide | |
TRIM29 | |
Recombinant fragment (126 Amino acid residues between aa 1-200) of human TRIM29 protein (Uniprot: Q14134) | |
0.1 mL | |
Primary | |
Human | |
IgG2b κ |
Western Blot, Flow Cytometry, Immunofluorescence | |
TRIM29/1042 | |
Western Blot, Flow Cytometry, Immunofluorescence | |
Ataxia telangiectasia group D-associated protein, ATDC, ATDC ataxia-telangiectasia group D-associated protein, FLJ36085, tripartite motif containing 29, tripartite motif protein TRIM29, tripartite motif-containing 29, tripartite motif-containing protein 29 | |
Mouse | |
Protein A or G purified | |
RUO | |
It recognizes a 66kDa protein, which is identified as Tripartite motif-containing protein 29 (TRIM29). It interacts with the intermediate filament protein vimentin, a substrate for the PKC family of protein kinases, and with hPKCI-1, an inhibitor of the PKCs. TRIM29 protein contains both zinc finger and leucine zipper motifs, suggesting that the it may form homodimers and possibly associate with DNA. High expression of TRIM29 has been reported in gastric cancer and pancreatic cancer, and correlates with enhanced tumor growth and lymph node metastasis. TRIM29 is also able to distinguish lung squamous cell carcinoma from lung adenocarcinoma with ∽90% positive accuracy, when used in a panel with TTF-1, p63, CK5/6, and Napsin-A antibodies. | |
Store at 4°C in the dark. |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction